Loading...
Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential
Mogamulizumab (KW-0761) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets CC chemokine receptor 4 (CCR4). It has shown promising therapeutic potential in phase I and II clinical trials and is currently being investigated for efficacy in treating cutaneous T-cell lymphoma...
Na minha lista:
| Udgivet i: | Ther Adv Hematol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4872175/ https://ncbi.nlm.nih.gov/pubmed/27247757 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716636541 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|